For consumers
(1300 633 424)
Mon-Fri | 9am-5pm AEST
Your call will be answered by healthdirect Australia
For health professionals
Find out the active ingredient and other brand names of your medicines with the NPS Medicine Name Finder
For a medicinewise Australia
Independent. Not-for-profit. Evidence based.
Site Tools
Janumet (metformin) - Independent medicine & health information for consumers & professionals Janumet (metformin) medicine information
Latest independent drug information about the Janumet brand of medicine and treatments, written and reviewed by experts in Australia.
Metformin is the active ingredient in the medicine brand Janumet.
Information about the brand Janumet
| Filter by audience: | |
|---|---|
| All | |
| Consumer | |
| Health professional | |
| Researchers & evaluators | |
| Members & stakeholders | |
| Other | |
| Title | Description | Type | Audience  |
Date* |
|---|---|---|---|---|
| Combination medicines - Independent medicine & health information | More than one type of medicine may be necessary to control blood glucose levels in people with type 2 diabetes. View our table of combination medicines used to control blood sugar levels. | Web page | Consumers,Others,Research & Evaluation community | 2011-11-14 00:00:00 |
| Sitagliptin with metformin (Janumet) fixed-dose combination tablets PBS listed for type 2 diabetes mellitus | Sitagliptin with metformin tablets (Janumet) have been PBS listed for the treatment of type 2 diabetes. The listing is restricted to people who have inadequate glycaemic control despite metformin, and cannot take metformin with a sulfonylurea, and for those who are already stabilised on metformin and sitagliptin. | Professional publication - NPS RADAR - Brief item | Health Professionals | 2009-08-01 00:00:00 |
| Postmarketing reports of acute pancreatitis with sitagliptin products (Janumet, Januvia) | Cases of acute pancreatitis have been reported with sitagliptin and sitagliptin with metformin. | Professional publication - NPS RADAR - Brief item | Health Professionals | 2010-04-01 00:00:00 |
| Janumet | Consumer Information from the manufacturer about the use of Janumet (Sitagliptin phosphate monohydrate and metformin hydrochloride). | Consumer publication - Consumer medicine information leaflet (CMI) | Consumers | 2010-10-27 00:00:00 |
Information about the active ingredient metformin
Most medicines have two names: the active ingredient name and the brand name. It’s important to be able to identify each of your medicines by the active ingredient as well as the brand name. Knowing the active ingredient name will help you avoid confusing your medicines.
There may be several brands that contain the same active ingredient. There may also be brands that contain multiple active ingredients. NPS aims to help people find information about their medicines easily, so brand information may be included, but not all brands may be listed. Reference to a brand does not mean NPS recommends one brand over another. If you are not sure about your medicine’s active ingredient(s), check the Medicines Name Finder, or ask your doctor or pharmacist.
Below is information on medicines that contain the active ingredient metformin.
| Title | Description | Type | Audience |
Date* |
|---|---|---|---|---|
| Medicines for type 2 diabetes - Independent medicine & health information | People with type 2 diabetes may need medicines as well as dietary changes & physical activity to control their blood glucose levels. Treating diabetes with medicines helps relieve symptoms & reduces the risk of developing complications. | Web page | Consumers,Others,Research & Evaluation community | 2011-11-14 00:00:00 |
| Gliptins - Independent medicine & health information | Gliptins is the nickname given a group of medicines called dipeptidyl peptidase-4 inhibitors. Sitagliptin, vildagliptin & saxagliptin control blood glucose levels in people with type 2 diabetes. Find out more about the benefits & side effects of gliptins. | Web page | Consumers,Others,Research & Evaluation community | 2011-11-14 00:00:00 |
| Metformin - Independent medicine & health information | Metformin is used to reduce blood glucose levels in people with type 2 diabetes. It can be used alone, or combined with other diabetes medicines, including insulin. Read more about the benefits & side effects of metformin. | Web page | Consumers,Others,Research & Evaluation community | 2011-11-14 00:00:00 |
| Combination medicines - Independent medicine & health information | More than one type of medicine may be necessary to control blood glucose levels in people with type 2 diabetes. View our table of combination medicines used to control blood sugar levels. | Web page | Consumers,Others,Research & Evaluation community | 2011-11-14 00:00:00 |
| What brands of metformin are available in Australia? - Independent medicine & health information | Metformin is available as many different brands. Read our list of brands of metformin available in Australia to treat type 2 diabetes. | Web page | Consumers,Others,Research & Evaluation community | 2011-11-14 00:00:00 |
| Sitagliptin with metformin (Janumet) fixed-dose combination tablets PBS listed for type 2 diabetes mellitus | Sitagliptin with metformin tablets (Janumet) have been PBS listed for the treatment of type 2 diabetes. The listing is restricted to people who have inadequate glycaemic control despite metformin, and cannot take metformin with a sulfonylurea, and for those who are already stabilised on metformin and sitagliptin. | Professional publication - NPS RADAR - Brief item | Health Professionals | 2009-08-01 00:00:00 |
| New York Heart Association grading of heart failure (NYHA) | Provides New York Heart Association grading of heart failure (NYHA) as additional content to rosiglitazone use for type 2 diabetes mellitus. | Professional publication - NPS RADAR - Web only item | Health Professionals | 2008-12-01 00:00:00 |
| Intolerance and contraindications to metformin | Lists adverse effects of and contraindications to metformin, including gastrointestinal symptoms, lactic acidodis, and renal impairment. | Professional publication - NPS RADAR - Web only item | Health Professionals | 2008-12-01 00:00:00 |
| Rosiglitazone (Avandia) and rosiglitazone with metformin (Avandamet) for type 2 diabetes mellitus | Information about use of Rosiglitazone (Avandia) and rosiglitazone with metformin (Avandamet) for type 2 diabetes mellitus | Professional publication - NPS RADAR - Review | Health Professionals | 2008-12-01 00:00:00 |
| Rosiglitazone with metformin combination tablets (Avandamet) listed on the PBS. | Rosiglitazone with metformin in a fixed-dose combination tablet (Avandamet) was listed on the PBS as a third-line choice, after metformin and/or a sulfonylurea. | Professional publication - NPS RADAR - Brief item | Health Professionals | 2006-12-01 00:00:00 |
| Intolerance and contraindications to metformin | Lists adverse effects of and contraindications to metformin, including gastrointestinal symptoms, lactic acidosis, and renal impairment. | Professional publication - NPS RADAR - Web only item | Health Professionals | 2008-04-01 00:00:00 |
| Vildagliptin with metformin (Galvumet) fixed-dose combination tablets PBS listed for type 2 diabetes | Vildagliptin with metformin tablets (Galvumet) are available on the PBS for the treatment of type 2 diabetes. | Professional publication - NPS RADAR - Brief item | Health Professionals | 2011-04-01 00:00:00 |
| Case study 55 report: Treatment options for neuropathic pain | Doris is a 64-year-old war widow with a 15-year history of well-controlled type 2 diabetes. She comes to you complaining of severe discomfort in her calves and feet. | Professional activity - Case study report | Health Professionals | 2009-01-30 00:00:00 |
| Case study 55: Treatment options for neuropathic pain | Doris is a 64-year-old war widow with a 15-year history of well-controlled type 2 diabetes. She comes to you complaining of severe discomfort in her calves and feet. | Professional activity - Case study | Health Professionals | 2008-10-01 00:00:00 |
| Case study 51 report: Managing persistent hyperglycaemia | Patient diagnosed with type 2 diabetes mellitus has a myocardial infarction and makes lifestyle changes. Examines optimal prescriptions when hyperglycaemia is persistent. | Professional activity - Case study report | Health Professionals | 2008-04-01 00:00:00 |
| Case study 36 report: Progressive management of type 2 diabetes | Patient with hypertension, occasional angina and type 2 diabetes presents for routine review. Recent blood sugar levels have been slowly increasing. | Professional activity - Case study report | Health Professionals | 2005-07-01 00:00:00 |
| Case study 28 report: Managing hypertension in diabetes | Patient with type 2 diabetes presents for review of his blood pressure (145/90 mmHg). His current medications are ramipril, simvastatin and metformin. | Professional activity - Case study report | Health Professionals | 2003-10-01 00:00:00 |
| Case study 16 report: Management of diabetes | Patient recently diagnosed with type 2 diabetes represents after trial of lifestyle measures. He has lost 2kg but his random blood glucose is 11.5 mmol/l. | Professional activity - Case study report | Health Professionals | 2001-10-01 00:00:00 |
| Case study 51: Managing persistent hyperglycaemia | Patient diagnosed with type 2 diabetes mellitus has a myocardial infarction and makes lifestyle changes. Examines optimal prescriptions when hyperglycaemia is persistent. | Professional activity - Case study | Health Professionals | 2008-02-01 00:00:00 |
| Case study 36: Progressive management of type 2 diabetes | Patient with hypertension, occasional angina and type 2 diabetes presents for routine review. Recent blood sugar levels have been slowly increasing. | Professional activity - Case study | Health Professionals | 2005-04-01 00:00:00 |
| Case study 28: Managing hypertension in diabetes | Patient with type 2 diabetes presents for review of his blood pressure (145/90 mmHg). His current medications are ramipril, simvastatin and metformin. | Professional activity - Case study | Health Professionals | 2003-08-01 00:00:00 |
| Case study 16: Management of type 2 diabetes | Patient recently diagnosed with type 2 diabetes represents after trial of lifestyle measures. He has lost 2kg but his random blood glucose is 11.5 mmol/l. | Professional activity - Case study | Health Professionals | 2001-08-01 00:00:00 |
| Type 2 diabetes - Managing hyperglycaemia | Reviews use of metformin and thiazolidinediones for type 2 diabetes, and provides simple guidelines for starting insulin. | Professional publication - NPS News | Health Professionals | 2008-02-01 00:00:00 |
| Type 2 diabetes - Reducing risk in | Ways to prevent cardiovascular disease by preventing and managing type 2 diabetes with lifestyle changes and treatment focused on metformin and insulin management. | Professional publication - NPS News | Health Professionals | 2005-04-01 00:00:00 |
| Antidiabetic drugs - type 2 diabetes | Oral therapy with older drugs as effective as insulin in Type 2 diabetes. Concerns over diabetes in Australian indigenous peoples. Includes case study. | Professional publication - NPS News | Health Professionals | 2001-08-01 00:00:00 |
| NPS Prescribing Practice Review 29: Reducing risk in type 2 diabetes | Information on assessing/managing cardiovascular risk factors, blood glucose control, and initiating insulin in patients with type 2 diabetes. Sample feedback prescribing data is also provided. | Professional publication - Prescribing Practice Review | Health Professionals | 2005-04-29 00:00:00 |
| NPS Prescribing Practice Review 29: Reducing risk in type 2 diabetes | Information on assessing/managing cardiovascular risk factors, blood glucose control, and initiating insulin in patients with type 2 diabetes. Sample feedback prescribing data is also provided. | Professional publication - Prescribing Practice Review | Health Professionals | 2005-04-29 00:00:00 |
| Metformin/glibenclamide (Glucovance) for type 2 diabetes mellitus | Reviews use of metformin/glibenclamide combination tablets for type 2 diabetes mellitus, including comparison with co-administered drugs and risk of hypoglycaemia. | Professional publication - NPS RADAR - Review | Health Professionals | 2005-12-01 00:00:00 |
| Effect of NPS diabetes program on metformin and insulin utilisation in the Australian veteran population, Abstract NMS 2010 | Metformin and insulin use concurrent with oral hypoglycaemics in the Australian veteran population before and after an NPS intervention. Gadzhanova S, Roughead L, Mackson J. National Medicine Symposium, 26-28 May 2010, Melbourne, Australia | Event - Conference abstract | Health Professionals,Research & Evaluation community | 2010-05-28 00:00:00 |
| Janumet | Consumer Information from the manufacturer about the use of Janumet (Sitagliptin phosphate monohydrate and metformin hydrochloride). | Consumer publication - Consumer medicine information leaflet (CMI) | Consumers | 2010-10-27 00:00:00 |
| Terry White Chemists Metformin | Consumer information from the manufacturer about the use of Terry White Chemists Metformin (metformin hydrochloride). | Consumer publication - Consumer medicine information leaflet (CMI) | Consumers | 2011-02-01 00:00:00 |
| Diaformin XR | Consumer information from the manufacturer about the use of Diaformin XR (metformin hydrochloride). | Consumer publication - Consumer medicine information leaflet (CMI) | Consumers | 2009-08-31 00:00:00 |
| Chemmart Metformin | Consumer information from the manufacturer about the use of Chemmart Metformin (metformin hydrochloride). | Consumer publication - Consumer medicine information leaflet (CMI) | Consumers | 2011-02-01 00:00:00 |
| NPS coordinates QUM program on type 2 diabetes | Promotion of NPS resources for professional continuing education on drug choices in type 2 diabetes. Includes decision-making about new drug options. | Media release | Consumers | 2005-04-12 00:00:00 |
| NPS coordinates QUM program on type 2 diabetes | Promotion of NPS resources for professional continuing education on drug choices in type 2 diabetes. Includes decision-making about new drug options. | Media release | Others | 2005-04-27 00:00:00 |
| Avandamet | Consumer information from the manufacturer about the use of Avandamet (rosiglitazone maleate and metformin hydrochloride). | Consumer publication - Consumer medicine information leaflet (CMI) | Consumers | 2011-03-15 00:00:00 |
| Glucovance | Consumer information from the manufacturer about the use of Glucovance (contains the active ingredients metformin hydrochloride and glibenclamide). | Consumer publication - Consumer medicine information leaflet (CMI) | Consumers | 2011-04-29 00:00:00 |
| Diaformin | Consumer information from the manufacturer about the use of Diaformin (contains the active ingredient metformin hydrochloride). | Consumer publication - Consumer medicine information leaflet (CMI) | Consumers | 2008-02-29 00:00 |
| Diabex XR | Consumer information from the manufacturer about the use of Diabex XR (contains the active ingredient metformin hydrochloride). | Consumer publication - Consumer medicine information leaflet (CMI) | Consumers | 2010-07-02 00:00:00 |
| Galvumet | Consumer information from the manufacturer about the use of Galvumet (vildagliptin/metformin hydrochloride). | Consumer publication - Consumer medicine information leaflet (CMI) | Consumers | 2011-01-25 00:00:00 |
| Apo-Metformin | Consumer information from the manufacturer about the use of Apo-Metformin (metformin hydrochloride). | Consumer publication - Consumer medicine information leaflet (CMI) | Consumers | 2011-01-31 00:00:00 |
| Should I change to a new medicine? A diabetes story | How someone with diabetes decided whether a new medicine was right for them. | Consumer resource - Story | Consumers | 2011-01-24 00:00:00 |
Information on this website is published by NPS — an independent, evidence based, not-for-profit organisation funded by the Australian Government Department of Health and Ageing.
NPS develops its information under the guidance of experts in their field, editorial panels, expert reviewers and consumers. Find out more about how we develop our content.
Date published: 2010-12-17 00:00:00
Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.
References to brands should not be taken as an endorsement by NPS.
